Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: a randomised controlled trialTrial registration number

Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea–Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night)

Role of non-muscular myosin light chain kinase (nmMLCK) in the inflammation associated with a model of intermittent hypoxia.

International audienc

nmMLCK a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc

nmMLCK a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc

Role of non-muscular myosin light chain kinase (nmMLCK) in the inflammation associated with a model of intermittent hypoxia.

International audienc

nmMLCK : a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc

nmMLCK : a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc

nmMLCK a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc

nmMLCK a key player in intermittent hypoxia-induced inflammatory vascular remodeling ?

International audienc